In a patient with bilateral neck level II small cell carcinoma with no apparent primary after workup with plans to receive concurrent cisplatin/etoposide, what would be your treatment volumes?   

Extrapulmonary small cell cancer, like its lung equivalent, is highly sensitive to chemotherapy but has a high rate of metastatic disease, which is the primary site of failure, with median DFS of about 6 months. If this patient achieves clinical CR after chemotherapy, I would forgo RT.  I would...